ALPS Group Inc.

20/04/2026

Less than six months after its Nasdaq debut, ALPS Group is shifting its focus toward addressing a key challenge in healthcare—bridging the gap in access to biotechnology.

As reported by The Business Times, this pivot reflects the group’s evolving strategy to expand accessibility and support broader adoption of advanced healthcare solutions across markets.

This marks an important step in aligning innovation with real-world healthcare needs.

It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people Read more at The Business Times.

17/04/2026

Alps Group Inc has appointed a former Ernst & Young partner, Hee H. Lee, to its Board of Directors — bringing over 35 years of global financial, advisory, and capital markets expertise to the table.

This strategic appointment reinforces the Group’s commitment to transparency, accountability, and long-term value creation as it continues to scale in the precision medicine and biotech space.

https://uk.finance.yahoo.com/news/alps-group-appoints-former-ernst-123000257.html

KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform focused on predictive, preventive, and precision medicine, announced ...

24/02/2026

ALPS Group Inc publishes clinical safety, tolerability & effectiveness data advancing its autologous NK cell pipeline using an in-house culture protocol. A key milestone in scalable immune cell therapy.

Read more: https://finance.yahoo.com/news/alps-group-inc-publishes-clinical-130000519.html

https://alps-holdings.com/alps-group-inc-publishes-clinical-safety-tolerability-and-effectiveness-data-supporting-advancement-of-its-autologous-nk-cell-pipeline-using-an-in-house-developed-culture-protocol/

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision...

16/02/2026

Wishing you health, prosperity, and happiness this Chinese New Year. 🧧✨

09/02/2026

Alps Group Inc announces a potential expansion of its exosome pipeline beyond CELESOME(+), following peer-reviewed clinical observations of nebulized hUCMSC-derived exosomes in asthma and COPD patients.

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precisio...

20/11/2025

[ ALPS ] Redefining Industries through Innovation & Insight
ALPS is proud to be featured by The Business Times for leading biotech transformation through innovation, precision, and purpose.
🔗 Read more: https://www.businesstimes.com.sg/events-awards/emerging-enterprise/redefining-industries-through-innovation-and-insight

👉 Also on ALPS News: https://alps-holdings.com/alps-group-driving-transformation-through-innovation-insight/

With the recent feature by The Business Times spotlighting the 2025 Emerging Enterprise Awards — themed “Redefining industries through innovation and insight”

12/11/2025

[ ALPS ] Redefining Biotech from Malaysia to the World

From Kuala Lumpur to NASDAQ, ALPS Group continues breaking barriers in biotechnology — not just by going global, but by making precision medicine accessible to all.

Founded by Dr. Tham Seng Kong, ALPS integrates AI, cell therapy, and full gene sequencing (99%+ accuracy) to create personalized vaccines and regenerative treatments for real-world impact.

“We didn’t build ALPS for wealth — we built it to make science serve humanity.”

As ALPS expands into Indonesia, the Middle East, and beyond, the mission remains the same: ethical science, human focus, and global reach.

🔗 Read more on World Journal: https://www.worldjournal.com/wj/story/121390/9131098?from=wj_catelistnews

馬來西亞華人譚鋮洸創立的 ALPS Group Inc.(ALPS)，於上月31日在那斯達克(Nasdaq)掛牌上市。該...

11/11/2025

[ ALPS ] 🌍 From Malaysia to the World: ALPS’ Mission to Democratize Advanced Healthcare
ALPS isn’t just a biotech company — it’s a story of passion, perseverance, and purpose.
After years of research and relentless innovation, ALPS continues to lead in regenerative medicine, immunotherapy, and mRNA technology — driven by a simple goal: making advanced medical treatments accessible to everyone.
As we expand globally following our NASDAQ milestone, our commitment remains the same — healing humanity through science and integrity. 💙

總部位於馬來西亞的生物科技與生命科學公司「阿爾卑斯集團」（ALPS Group Inc.），10月31日在納斯達克（NASDAQ）掛牌上市，11月6日，馬來西亞旅美聯誼會董事局主席邦君雄在法拉盛設宴，歡迎該公司董事會主席譚鋮洸博士（Dr. Tham...

07/11/2025

[ ALPS ] We rang the Nasdaq Closing Bell in Times Square! A proud milestone for ALPS Group Inc. (NASDAQ: ALPS) as Founder & Group CEO Dr. Tham Seng Kong shares our vision to advance predictive, preventive, and precision medicine across Southeast Asia and beyond. Watch the speech:

https://www.nasdaq.com/events/alps-group-inc-rings-closing-bell

https://alps-holdings.com/alps-group-rings-nasdaq-closing-bell-in-new-york/

01/11/2025

[ ALPS ] Today marks a definitive milestone for ALPS as we join Nasdaq’s global stage. What began as a lifelong passion in genomics and cellular research has evolved into a mission to redefine the future of healthcare.

**C

Alps ordinary shares to list on the Nasdaq under the symbol “ALPS” on October 31, 2025

27/05/2025

[ ALPS Global Holding Berhad ] ALPS is proud to be recognised as an official contributor to Malaysia’s vaccine scoring framework, MyPRICISE.
👏 Congrats to Prof. Manickam Ravichandran for his national recognition by the Ministry of Health!
🔗 Read more:

ALPS Global Holding Berhad is officially recognised as a contributor to MyPRICISE, Malaysia’s national vaccine prioritisation framework led by the Ministry of Health.